Small cell lung cancer (SCLC) is the most common neuroendocrine tumor in the lungs. SCLC is characterized by high malignancy and high recurrence and metastasis rates. The improvement of the prognosis of patients with SCLC relies on early diagnosis, correct staging, and accurate assessment of efficacy and prognosis. In this paper, we comprehensively analyze the application progress of 18F-fluorodeoxyglucose (FDG) PET/CT as well as the tumor markers neuron-specific enolase (NSE) and gastrin-releasing peptide precursor (ProGRP) in the diagnosis and treatment of SCLC. Our results can be useful for the diagnosis and treatment of SCLC patients in clinical practice
